This website is intended for international healthcare professionals with an interest in the treatment of Nocturia. By clicking the link below you are declaring and confirming that you are a healthcare professional. Please answer a few short questions about this resource centre.

You are here

Karl-Erik Andersson, MD, PhD, Professor

Introduction to Prof. Karl-Erik Andersson:

Professor Andersson's research interests include urogenital and cardiovascular pharmacology and physiology, clinical trials, regenerative medicine and regenerative pharmacology. His interest in nocturia stems from his background in internal medicine and clinical pharmacology, and from an interest in the physiology and pharmacology of vasopressin.


Professor Andersson is currently visiting professor of Vascular and Urogenital Pharmacology, University of Aarhus, Denmark. He received his medical degree from the University of Lund in 1968, and completed his Ph.D. at the Department of Pharmacology, Lund University, in 1973. In 1975 he obtained a Swedish specialist degree in Internal Medicine and was appointed as Professor of Clinical Pharmacology at the University of Odense, Denmark. From 1976 to 1978 he had the same position at the University of Aarhus, Denmark. From 1978-2006 he was Professor and Chairman of the Department of Clinical Pharmacology, University of Lund, Lund, Sweden, and from 2006 he is professor at Wake Forest Institute for Regenerative Medicine, Wake Forest University, Winston-Salem, North Carolina. He is a member of many international societies including the American Urological Association, the European Association of Urology, and the International Society for Sexual and Impotence Research. He is currently acting as section editor of Investigative Urology (Journal of Urology), Neurourology and Urodynamics, and World Journal of Urology, and serves on the Editorial Boards of several other journals including European Urology, International Journal of Impotence Research, International Journal of Urology, and LUTS. During his career, Professor Andersson has authored more than 800 articles in peer-reviewed international journals.

Dr Andersson has a longstanding interest in bladder physiology and pathophysiology and in the pharmacological management of bladder dysfunctions, including OAB and its role in nocturia. He is also specifically interested in the spectrum of systemic diseases that can be associated with nocturia.

Conflict of Interest: Professor Andersson is Consultant and part of the Advisory Board of: Allergan, Astellas, Ferring

The Role of the Editor
The editorial independence of the resource centre is mandatory and recognized by the EAU and Elsevier. The journal articles and other material published on the resource centre have been selected independently and without influence from Elsevier, European
Urology Editors or the sponsor.